Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
Introduction Dry mouth is the main symptom of sicca syndrome, which rarely occurs as an immune‐related adverse event. Here we report a case of sicca syndrome caused by immune checkpoint inhibitor treatment. Case presentation A 70‐year‐old man was diagnosed with left renal cell carcinoma after radica...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | IJU Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iju5.12573 |
| _version_ | 1811161892572364800 |
|---|---|
| author | Takuya Segawa Takanobu Motoshima Junji Yatsuda Ryoma Kurahashi Yumi Fukushima Yoji Murakami Takahiro Yamaguchi Yutaka Sugiyama Ryoji Yoshida Hideki Nakayama Tomomi Kamba |
| author_facet | Takuya Segawa Takanobu Motoshima Junji Yatsuda Ryoma Kurahashi Yumi Fukushima Yoji Murakami Takahiro Yamaguchi Yutaka Sugiyama Ryoji Yoshida Hideki Nakayama Tomomi Kamba |
| author_sort | Takuya Segawa |
| collection | DOAJ |
| description | Introduction Dry mouth is the main symptom of sicca syndrome, which rarely occurs as an immune‐related adverse event. Here we report a case of sicca syndrome caused by immune checkpoint inhibitor treatment. Case presentation A 70‐year‐old man was diagnosed with left renal cell carcinoma after radical left nephrectomy. Nine years later, computed tomography revealed a metastatic nodule in the upper left lung lobe. Subsequently, ipilimumab and nivolumab were administered for recurrent disease. After 13 weeks of treatment, xerostomia and dysgeusia were noted. Salivary gland biopsy revealed lymphocyte and plasma cell infiltration in the salivary glands. Sicca syndrome was diagnosed and pilocarpine hydrochloride was prescribed without corticosteroids, with continuation of immune checkpoint inhibitor therapy. The symptoms alleviated after 36 weeks of treatment, with shrinkage of the metastatic lesions. Conclusion We experienced sicca syndrome caused by immune checkpoint inhibitors. Sicca syndrome improved without steroids and the immunotherapy could be continued. |
| first_indexed | 2024-04-10T06:21:20Z |
| format | Article |
| id | doaj.art-1e82b6c18bc44d6b9f3753bf0f2a9eac |
| institution | Directory Open Access Journal |
| issn | 2577-171X |
| language | English |
| last_indexed | 2024-04-10T06:21:20Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | IJU Case Reports |
| spelling | doaj.art-1e82b6c18bc44d6b9f3753bf0f2a9eac2023-03-02T04:40:25ZengWileyIJU Case Reports2577-171X2023-03-016214714910.1002/iju5.12573Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinomaTakuya Segawa0Takanobu Motoshima1Junji Yatsuda2Ryoma Kurahashi3Yumi Fukushima4Yoji Murakami5Takahiro Yamaguchi6Yutaka Sugiyama7Ryoji Yoshida8Hideki Nakayama9Tomomi Kamba10Department of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanDepartment of Oral and Maxillofacial Surgery Kumamoto University Kumamoto JapanDepartment of Oral and Maxillofacial Surgery Kumamoto University Kumamoto JapanDepartment of Urology Kumamoto University Kumamoto JapanIntroduction Dry mouth is the main symptom of sicca syndrome, which rarely occurs as an immune‐related adverse event. Here we report a case of sicca syndrome caused by immune checkpoint inhibitor treatment. Case presentation A 70‐year‐old man was diagnosed with left renal cell carcinoma after radical left nephrectomy. Nine years later, computed tomography revealed a metastatic nodule in the upper left lung lobe. Subsequently, ipilimumab and nivolumab were administered for recurrent disease. After 13 weeks of treatment, xerostomia and dysgeusia were noted. Salivary gland biopsy revealed lymphocyte and plasma cell infiltration in the salivary glands. Sicca syndrome was diagnosed and pilocarpine hydrochloride was prescribed without corticosteroids, with continuation of immune checkpoint inhibitor therapy. The symptoms alleviated after 36 weeks of treatment, with shrinkage of the metastatic lesions. Conclusion We experienced sicca syndrome caused by immune checkpoint inhibitors. Sicca syndrome improved without steroids and the immunotherapy could be continued.https://doi.org/10.1002/iju5.12573immune checkpoint inhibitorimmune‐related adverse eventpilocarpinesicca syndromexerostomia |
| spellingShingle | Takuya Segawa Takanobu Motoshima Junji Yatsuda Ryoma Kurahashi Yumi Fukushima Yoji Murakami Takahiro Yamaguchi Yutaka Sugiyama Ryoji Yoshida Hideki Nakayama Tomomi Kamba Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma IJU Case Reports immune checkpoint inhibitor immune‐related adverse event pilocarpine sicca syndrome xerostomia |
| title | Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma |
| title_full | Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma |
| title_fullStr | Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma |
| title_full_unstemmed | Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma |
| title_short | Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma |
| title_sort | sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma |
| topic | immune checkpoint inhibitor immune‐related adverse event pilocarpine sicca syndrome xerostomia |
| url | https://doi.org/10.1002/iju5.12573 |
| work_keys_str_mv | AT takuyasegawa siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT takanobumotoshima siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT junjiyatsuda siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT ryomakurahashi siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT yumifukushima siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT yojimurakami siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT takahiroyamaguchi siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT yutakasugiyama siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT ryojiyoshida siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT hidekinakayama siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma AT tomomikamba siccasyndromeduringipilimumabandnivolumabtherapyformetastaticrenalcellcarcinoma |